Skip to main content
Medical information Clinical review pending

Genetic Testing

KAT6A Gene Mental Retardation Autosomal Dominant Type 32 Genetic Test

The KAT6A Gene Mental Retardation Autosomal Dominant Type 32 NGS Genetic DNA Test identifies mutations in the KAT6A gene associated with neurological disorders and developmental delays. This test uses Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient and a genetic counseling session, including a pedigree chart of affected family members, are recommended before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the KAT6A Gene Mental Retardation Autosomal Dominant Type 32 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with developmental delays or cognitive impairments.
  • ✓Family history of KAT6A-related disorders.
  • ✓Individuals with features suggestive of KAT6A-related disorders.
  • ✓Genetic counseling for families with affected members.
  • ✓Prenatal diagnosis in high-risk pregnancies (requires specialist consultation).
02

In plain language

What this test helps you understand

This test helps identify mutations in the KAT6A gene, which can confirm a diagnosis of KAT6A-related disorders, provide information for genetic counseling, and potentially guide management strategies for individuals with developmental delays or cognitive impairments.
The KAT6A Gene Mental Retardation Autosomal Dominant Type 32 NGS Genetic DNA Test is a specialized genetic test designed to detect mutations within the KAT6A gene. Mutations in this gene are known to be associated with certain neurological disorders, including developmental delays and cognitive impairments. This test is particularly relevant for families with a history of these conditions, offering valuable information for understanding the genetic basis of the disorder and guiding management strategies.

This test utilizes advanced Next-Generation Sequencing (NGS) technology to analyze DNA samples for specific variations in the KAT6A gene. By identifying these genetic changes, the test can help confirm a diagnosis or assess the risk of developing related conditions.

Understanding the results requires consultation with a healthcare professional or genetic counselor who can interpret the findings in the context of the individual's clinical history and family background.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient and a genetic counseling session, including a pedigree chart of affected family members, are recommended before testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) of the KAT6A gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects mutations within the KAT6A gene but may not identify all possible genetic causes of developmental delays or cognitive impairments. Results should be interpreted in the context of clinical findings. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The KAT6A gene provides instructions for making a protein involved in gene regulation and development. Mutations in this gene can lead to neurological disorders.
Individuals with developmental delays, cognitive impairments, or a family history of related conditions may be candidates for this test. Consultation with a doctor is recommended.
A sample can be collected as a blood draw, using extracted DNA, or even a single drop of blood on a special card. Home sample collection may be available.
The typical turnaround time is around 3 to 4 weeks, but this can vary. Please confirm the current turnaround time with the laboratory.
It is crucial to discuss your results with a healthcare provider or genetic counselor. They can help interpret the findings and discuss potential implications and next steps.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp